Should You Buy Alpha Tau Medical Ltd. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Alpha Tau Medical Ltd. (DRTS) sits in the bottom tier of our quality coverage with a score of 2.6/10. While a weak quality score suggests operational challenges, our valuation models assess if the market has over-discounted the stock at $14.87.
The short answer: 0 of 0 CirclFi valuation models project upside for Alpha Tau Medical Ltd. (DRTS) at $14.87 — the models are evenly split, with a Quality Score of 2.6/10 and Value-Trap risk of 40/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Alpha Tau Medical Ltd. (DRTS) in 2026?
What Is the Bull Case vs the Bear Case for Alpha Tau Medical Ltd. (DRTS)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for DRTS at $14.87. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for DRTS. The Value Trap score of 40/100 still argues for some caution. |
How Does DRTS Compare to Its Biotechnology Peers?
Valuation data pages: YDES · PHAR · MAJI · OKYO · ARGX · XTLB · IOVA · SER · ENSC · EXEL · INCY
Which Other Stocks Score Like DRTS on Quality?
Closest companies to DRTS’s Quality of Company score of 2.6/10, across all industries.
- ZKIN — ZK International Group Co., Ltd. (QOC 2.6) · analysis
- HSBC — HSBC Holdings plc (QOC 2.6) · analysis
- CNL — Collective Mining Ltd. (QOC 2.6) · analysis
- APWC — Asia Pacific Wire & Cable Corporation Limited (QOC 2.6) · analysis
- VALE — Vale S.A. (QOC 2.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does DRTS Appear In?
So Is Alpha Tau Medical Ltd. (DRTS) Worth Buying in 2026?
Alpha Tau Medical Ltd. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Alpha Tau Medical Ltd.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About DRTS Stock?
Should I buy DRTS stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for DRTS at $14.87. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Alpha Tau Medical Ltd.?
Key risks include: an elevated Value Trap score of 40/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 2.6/10, indicating fundamental weakness; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does DRTS compare to its competitors?
Among Biotechnology peers, DRTS holds a Quality Score of 2.6/10. Comparable companies include YDES (QOC 2.8), PHAR (QOC 2.6), MAJI (QOC 2.9). The relative ranking helps investors identify whether DRTS offers better fundamental quality than alternatives in the same sector.
Is DRTS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. DRTS's Quality Score of 2.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy DRTS at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for DRTS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad